Classement en actions
#23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Prix de l'action
$1.81
Dernière synchronisation: 2026-08-21
Capitalisation boursière
$77.00M
Changement (1 jour)
1.30%
Changement (1 an)
-23.63%
Échange Annovis Bio, Inc. (ANVS)
Le prix ANVS avec la capitalisation boursière de B
Capitalisation boursière de Annovis Bio, Inc.(ANVS)
Capitalisation boursière: $77.00M
En August 2026, Annovis Bio, Inc. a une capitalisation boursière de $77.00M. Cela fait de Annovis Bio, Inc. la 23205th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Annovis Bio, Inc. du 2020 au 2026
ANVS par rapport au top 5 des plus populaires stocks
| Prix pour ANVS |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.211T
|
+6,767,871.37%
|
|
|
|
|
$4.547T
|
+5,904,729.87%
|
|
|
|
|
$4.162T
|
+5,405,680.85%
|
|
|
|
|
$3.593T
|
+4,665,834.28%
|
|
|
|
|
$2.793T
|
+3,626,962.00%
|
